title: Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
abstract: In various clinical studies, Hodgkin's patients have been treated with anti-CD30 immunotherapeutic agents and have shown promising responses. One of the problems that appeared from these studies is the development of an immune response against the nonhuman therapeutics, which limits repeated administration and reduces efficacy. We have set out to make a recombinant, human anti-CD30 single-chain variable fragment (scFv) antibody, which may serve as a targeting moiety with reduced immunogenicity and more rapid tumour penetration in similar clinical applications. Rather than selecting a naive phage antibody library on recombinant CD30 antigen, we used guided selection of a murine antibody in combination with panning on the CD30-positive cell line L540. The murine monoclonal antibody Ki-4 was chosen as starting antibody, because it inhibits the shedding of the extracellular part of the CD30 antigen. This makes the antibody better suited for CD30-targeting than most other anti-CD30 antibodies. We have previously isolated the murine Ki-4 scFv by selecting a mini-library of hybridoma-derived phage scFv-antibodies via panning on L540 cells. Here, we report that phage display technology was successfully used to obtain a human Ki-4 scFv version by guided selection. The murine variable heavy (VH) and light (VL) chain genes of the Ki-4 scFv were sequentially replaced by human V gene repertoires, while retaining only the major determinant for epitope-specificity: the heavy-chain complementarity determining region 3 (CDR3) of murine Ki-4. After two rounds of chain shuffling and selection by panning on L540 cells, a fully human anti-CD30 scFv was selected. It competes with the parental monoclonal antibody Ki-4 for binding to CD30, inhibits the shedding of the extracellular part of the CD30 receptor from L540 cells and is thus a promising candidate for the generation of anti-CD30 immunotherapeutics.
authors.affiliation: Department of Internal Medicine I, University Hospital Cologne, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Klimka
authors.forename: B
authors.initials: B
authors.lastname: Matthey
authors.forename: R C
authors.initials: RC
authors.lastname: Roovers
authors.forename: S
authors.initials: S
authors.lastname: Barth
authors.forename: J W
authors.initials: JW
authors.lastname: Arends
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.forename: H R
authors.initials: HR
authors.lastname: Hoogenboom
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000915:Antibody Affinity; D001666:Binding Sites, Antibody; D003001:Cloning, Molecular; D006801:Humans; D006825:Hybridomas; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology*; D017730:Ki-1 Antigen / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008969:Molecular Sequence Data; D019151:Peptide Library; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D017386:Sequence Homology, Amino Acid
chemical_list: D007135:Immunoglobulin Variable Region; D017730:Ki-1 Antigen; D019151:Peptide Library; D011993:Recombinant Fusion Proteins